iOnctura and Clavius exercise option for TGF-β pathway inhibitorTGF-β pathway inhibitor

03 May 2023
www.pharmaceutical-technology.com
iOnctura and Clavius exercise option for TGF-β pathway inhibitor
Preview
Source: Pharmaceutical Technology
iOnctura will exclusively develop and commercialise IOA-359 worldwide. Credit: Mongkolchon Akesin via shutterstock.com.
Clavius Pharmaceuticals and iOnctura have exercised an option to add the IOA-359 oral TGF-β pathway inhibitorTGF-β pathway inhibitor to iOnctura’s pipeline.
The move is based on iOnctura’s approach of targeting a range of cancer survival pathways with a single drug.
Recommended Reports
iOnctura and Clavius exercise option for TGF-β pathway inhibitor
Preview
Source: Pharmaceutical Technology
ReportsCalcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) Drugs in Development b... GlobalData
iOnctura and Clavius exercise option for TGF-β pathway inhibitor
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Metformin + Dapagliflozin + Sitagliptin) in Type 2 Diabetes GlobalData
View all
It will help the firm target therapy resistance and immune evasion pathways, along with IOA-359’s direct impact on the tumour.
iOnctura will exclusively develop and commercialise IOA-359 across the globe.
In partnership with the University of Twente (UT), the company has received a grant from Health Holland and the Dutch Cancer Society (KWF).
Led by UT medical cell biophysics assistant professor Dr Ruchi Bansal, the KWF grant supplements iOnctura’s internal preclinical investigations.
The grant will see the use of UT’s model system to help iOnctura with a preclinical pharmacology package for IOA-359 in cancer.
The TGF-β pathway, which plays a vital role in supporting tumour aggression, immune escape and resistance to therapy, is becoming a target for therapy to treat cancer.
iOnctura CEO Catherine Pickering stated: “TGF-β is an established target in oncology, yet we are the first company applying precision methods to intelligently combine targeting this pathway alongside other tumour survival and resistance pathways.
“We recently demonstrated that the autotaxin/LPA pathway has a role in mediating TGF-β resistance in pancreatic cancer, and are excited to further explore combining IOA-359 with our autotaxin inhibitorautotaxin inhibitor, IOA-289, preclinically.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.